1. Palantir remains a buy recommendation due to strong fundamentals and an adjusted PEG ratio of 3.1x, suggesting undervaluation despite high multiples; 2. Accelerating revenue growth (48% YoY in Q2, 93% surge in U.S. commercial revenue) supports a bullish 2026 outlook; 3. Risks include potential valuation compression if growth slows, but execution could unlock long-term upside toward $3.5B FCF and 35%+ growth.